Penumbra, Inc. PEN

Zacks Investment Research 1 oct

In a comparison of two medical instruments sector stocks, Integra LifeSciences (IART) emerges as the better value opportunity for investors compared to Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.62 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.18 and Value grade of D. IART's superior valuation metrics and improving earnings outlook make it the more attractive choice for value investors.

Zacks Investment Research 29 sept

A comparison of two medical instruments companies reveals that Integra LifeSciences (IART) presents a more attractive value opportunity than Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.61 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.35 and Value grade of D. IART's stronger earnings estimate revisions and superior valuation metrics make it the preferred choice for value investors.

Zacks Investment Research 16 sept

Penumbra (PEN) reported Q2 2026 revenues up 14.9% driven by thrombectomy and embolization products, with international sales growing 7.6% across 100+ countries. However, SG&A expenses grew faster than revenues at 24.1%, causing operating margins to compress. Foreign exchange exposure and macroeconomic sensitivity pose risks, though the company maintains a Zacks Rank #3 (Buy) rating with shares up 21.1% over the past year.

GlobeNewswire Inc. 25 ago

Incuvate has filed a patent-infringement lawsuit against Penumbra in U.S. District Court for the Northern District of California, alleging that Penumbra's THUNDERBOLT Neurovascular Thrombectomy System and related components infringe five Incuvate patents covering real-time aspiration monitoring technology. Incuvate is seeking damages, injunctive relief, and other remedies.

GlobeNewswire Inc. 6 jul

GuideAI Health Corp. announced the appointment of renowned interventional radiologist Dr. James Benenati, Chief Medical Officer of Penumbra Inc., to its Advisory Board following FDA 510(k) clearance of its VAOT software. VAOT is an AI-based triage tool designed to assist radiologists in identifying peripheral arterial disease and vascular occlusion in the lower extremities to enable earlier diagnosis and intervention.